Search

Your search keyword '"Kaplan, Richard"' showing total 2,592 results

Search Constraints

Start Over You searched for: Author "Kaplan, Richard" Remove constraint Author: "Kaplan, Richard"
2,592 results on '"Kaplan, Richard"'

Search Results

1. Performance of Automated Machine Learning in Predicting Outcomes of Pneumatic Retinopexy.

2. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

5. Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictors

6. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

7. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

8. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

11. THE DECLINING APPEAL OF INHERITED RETIREMENT ACCOUNTS

12. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

13. PREFERENCING NONMARRIAGE IN LATER YEARS

14. Pneumatic Retinopexy Experience and Outcomes of Vitreoretinal Fellows in the United States A Multicenter Study

15. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

16. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

19. DNM1 encephalopathy

20. Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes

21. DNM1 encephalopathy: A new disease of vesicle fission.

22. Uterine Body Stuffing Confirmed by Computed Tomography

24. Fine-mapping analysis including over 254 000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

25. Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.

26. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

28. Ocular Imaging

30. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

31. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

32. #159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis

34. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

37. Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial

40. Sony Issues the First Volume of Columbia Stereo Recordings by Eugene Ormandy and the Philadelphia Orchestra.

41. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

44. A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists

45. ANALYZING THE NEW PLANNING OPPORTUNITIES IN SECURE 2.0 FOR RETIREMENT PLAN PARTICIPANTS.

47. Contributors

48. Supplementary Table 1 from Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

49. supplementary figures, from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

50. Supplementary Results from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

Catalog

Books, media, physical & digital resources